Evidence map›Paper›PMID 26988706›Full record

ArticleGenome medicine2016

A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses.

Kivia A P de Oliveira, Eva Kaergel, Matthias Heinig, Jean-Fred Fontaine, Giannino Patone, Enrique M Muro, Stephan Mathas, Michael Hummel, Miguel A Andrade-Navarro, Norbert Hübner and 1 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Genome medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05490953 (Enhancing Effect on Tumour Apoptosis With the Combined Use of Pentoxifylline Plus Chemotherapeutical Agents in Pediatrics and AYA Patients With Hodgkin´s Lymphoma), which is not on this map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05490953 phase4unknown statusnot on this mapstarted 2022, after this paper: background citation

Enhancing Effect on Tumour Apoptosis With the Combined Use of Pentoxifylline Plus Chemotherapeutical Agents in Pediatrics and AYA Patients With Hodgkin´s Lymphoma

TypeinterventionalSponsorUniversity of GuadalajaraRan2022 to 2024Enrolled30ConditionsHodgkin LymphomaArmsPentoxifylline, Placebo
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. MALT1 substrate cleavage: what is it good for?Frontiers in immunology · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Transcription factorZoological research · 2023
    Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Kivia A P de OliveiraSignal Transduction in Tumor Cells, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125, Berlin, Germany.
Eva KaergelSignal Transduction in Tumor Cells, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125, Berlin, Germany.
Matthias HeinigDepartment of Computational Biology, Max Planck Institute for Molecular Genetics, 14195, Berlin, Germany.
Jean-Fred FontaineComputational Biology and Data Mining, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125, Berlin, Germany.
Giannino PatoneGenetics and Genomics of Cardiovascular Diseases, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125, Berlin, Germany.
Enrique M MuroComputational Biology and Data Mining, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125, Berlin, Germany.
Stephan MathasMax-Delbrück-Center for Molecular Medicine, 13125, Berlin, Germany.
Michael HummelInstitute of Pathology, Charité-Universitätsmedizin Berlin, 10117, Berlin, Germany.
Miguel A Andrade-NavarroComputational Biology and Data Mining, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125, Berlin, Germany.
Norbert HübnerGenetics and Genomics of Cardiovascular Diseases, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125, Berlin, Germany.
Claus ScheidereitSignal Transduction in Tumor Cells, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Strasse 10, 13125, Berlin, Germany. Scheidereit@mdc-berlin.de.
Max Delbrück Center · DECharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNF-κB is widely involved in lymphoid malignancies; however, the functional roles and specific transcriptomes of NF-κB dimers with distinct subunit compositions have been unclear.

methodsUsing combined ChIP-sequencing and microarray analyses, we determined the cistromes and target gene signatures of canonical and non-canonical NF-κB species in Hodgkin lymphoma (HL) cells.

resultsWe found that the various NF-κB subunits are recruited to regions with redundant κB motifs in a large number of genes. Yet canonical and non-canonical NF-κB dimers up- and downregulate gene sets that are both distinct and overlapping, and are associated with diverse biological functions. p50 and p52 are formed through NIK-dependent p105 and p100 precursor processing in HL cells and are the predominant DNA binding subunits. Logistic regression analyses of combinations of the p50, p52, RelA, and RelB subunits in binding regions that have been assigned to genes they regulate reveal a cross-contribution of p52 and p50 to canonical and non-canonical transcriptomes. These analyses also indicate that the subunit occupancy pattern of NF-κB binding regions and their distance from the genes they regulate are determinants of gene activation versus repression. The pathway-specific signatures of activated and repressed genes distinguish HL from other NF-κB-associated lymphoid malignancies and inversely correlate with gene expression patterns in normal germinal center B cells, which are presumed to be the precursors of HL cells.

conclusionsWe provide insights that are relevant for lymphomas with constitutive NF-κB activation and generally for the decoding of the mechanisms of differential gene regulation through canonical and non-canonical NF-κB signaling.

Indexed as

Genome-Wide Association StudyBinding SitesCell Line, TumorCell SurvivalChromatin ImmunoprecipitationComputational BiologyDatabases, Nucleic AcidGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHodgkin DiseaseHumansI-kappa B KinaseNF-kappa BNF-kappa B p50 SubunitNF-kappa B p52 SubunitNucleotide MotifsI-kappa B KinaseNF-kappa BNF-kappa B p50 SubunitNF-kappa B p52 SubunitTranscription Factor RelATranscription Factor RelBB lymphocytescell deathChIP sequencingconsensus sequenceenhancergene expressioninflammationlymphomapromoterTranscription factor

Identifiers

PMID26988706
PMCPMC4794921
OpenAlexW2308295083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.